Clinical trials: Parvovirus B19 Infection

Parvovirus B19 Infection

B-19 Parvovirus Vaccine Study

• Terminated
• Age: 18 to 45 years
• Phase 1/2
• Vaccines

This study investigates the safety and effectiveness of a preventative vaccine for parvovirus B-19 infection. Eighty-nine healthy adults ages 18-49, whose blood tests negative for B-19, will be enrolled.

Trial name

NCT00379938

Testing

VAI-VP705 (parvovirus B-19 vaccine), MF-59

Where

3 sites in United States

Volunteers

43 people, healthy volunteers welcome

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)